2008
Ipsogen was transformed into a S.A.

Entry on the breast cancer diagnostic market with the European launch of MapQuant Dx™ Genomic Grade

Ipsogen is listed on Alternext, NYSE Euronext Paris

2007
License agreements with Warnex and Labcorp for JAK2 V617F diagnosis test commercialization in Canada and USA.

Collaboration agreement with Affymetrix (USA), world leader in the microarray field.

Partnership agreement with DNA Vision (Belgium) to offer diagnosis tests in breast cancer.

Licence agreement with Université Libre de Bruxelles for Genomic Grade index in breast cancer.

2006
Licence agreement with Institut Gustave Roussy, INSERM and Assistance Publique des Hôpitaux de Paris for JAK2 V617F mutation in blood cancer.

Licence agreement with Chicago University for BAALC marker in blood cancer.
First multicentric clinical trial in breast cancer.

2005
Fondation of Ipsogen Inc., Connecticut, USA.

2004
Second license agreement with the pharmaceutical group Genzyme (USA) for WT1 marker.

Commercial launch of the CE marked BCR-ABL FusionQuant® test.

2003
First licence agreement for FusionQuant® and ProfileQuant® technologies dedicated to blood cancer diagnosis.

2001
First round of fund raising, more than 5 million euros.

2000
R&D partnership with Institut Paoli-Calmettes, Marseilles, France.

1999
Foundation of Ipsogen SAS by Vincent Fert, Stéphane Debono, FabienneHermitte et Bertrand Jordan.